There’s a question a lot of research sites are quietly asking right now: what would a sponsor think if they found out we were using AI on their trial data at all?

In this packed episode of Note to File, Oliver joins Brad Hightower and Denali Rose to talk about what’s on the mind of any site leader right now: How do sponsors actually feel about sites using AI, and what does the FDA have to say about it? Does eSource even need to exist? Why is data entry still such an unsolved problem in clinical research? What does the future of paper source look like? Oliver gets into Gleam's novel approach and how it's quietly revolutionizing the hands-on workflows and daily operations at sites, how the team infuses fun in a serious work tool, and more.

I say this a lot when I’m building Gleam: I optimize for joy.

A lot of clinical research software is selected by people who are not doing the day-to-day work at the site. They're not the ones handling queries, entering data, or trying to keep visits, documentation, and patient care moving at the same time.

In clinical research, trust depends on being able to verify the work.

Clinical research sites already have enough competing for attention: Source pages, CRFs, queries, patient visits, and study timelines all demand focus. Software should make that work easier, not add another layer to manage.

How do startups find product-market fit? Oliver sits down with Adam O'Donnell to discuss Gleam's journey of self-discovery, forming authentic connections with the people whose challenges you've set out to solve, some wise words from Warren Buffett, and more.